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The subcutaneous implantable cardioverter-deﬁbrillator
(S-ICD) is an effective alternative to the conventional
transvenous ICD (TV-ICD) system in patients that can be
employed without the need for antitachycardia or antibrady-
cardia pacing.1,2 Because the risk associated with a TV-ICD
increases over time,3 populations in which there may be a
preference for an S-ICD include younger patients, those with
channelopathies, and those at high risk of complications with
a TV-ICD.
Brugada syndrome (BrS) is an arrhythmogenic disease
that mainly affects middle-aged men and causes sudden
cardiac death owing to ventricular ﬁbrillation. Whereas ICD
implantation is considered the main therapy in symptomatic
patients, the TV-ICD has been associated with high compli-
cation rates in BrS patients ﬁtted with an ICD.4 The S-ICD is
an appealing alternative choice for BrS patients. However,
the Brugada-pattern electrocardiogram (ECG) is known to
show dynamic changes, and the accuracy of ECG discrim-
ination is a concern with S-ICD implantation in patients with
BrS. A drug challenge test may serve as a useful screening
tool for patient eligibility to receive an S-ICD. Here, we
report a case of T-wave oversensing (TWOS) during a
drug challenge test after S-ICD implantation in a patient
with BrS.KEYWORDS Brugada syndrome; Subcutaneous implantable cardioverter-
deﬁbrillator; T-wave oversensing; Drug challenge test; Electrocardiogram
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A 51-year-old man with BrS was referred to our hospital in
consideration for ICD implantation. His baseline ECG
showed a spontaneous type 1 ECG in lead V1 in the third
intercostal space (Figure 1A). Although the patient had no
episodes of cardiac arrest or syncope, he had a strong family
history of sudden cardiac death (his grandmother and cousin
died suddenly during sleep at the ages of 48 and 31,
respectively). No cardiac abnormality was observed by
transthoracic echocardiography, and a standard 12-lead
ECG was normal except for incomplete right bundle branch
block (Figure 1A). Implantation of an S-ICD was considered
because ventricular ﬁbrillation was induced in an electro-
physiological study. Screening for S-ICD sensing in a
standard left parasternal lead position showed adequate
sensing in all 3 sensing vectors in both standing and supine
positions (Figure 2A). The S-ICD (EMBLEM; Boston
Scientiﬁc, Marlborough, MA) was successfully implanted
on the left side of the thorax using a standard technique
(Figure 1B).
On the day following S-ICD implantation, only a type 2
Brugada-pattern ECG was observed in the baseline ECG,
even in high costal ECG recordings (Figure 1C). A screening
ECG employing a standard left parasternal lead position
showed adequate sensing only in vector III (Figure 2B). The
other sensing vectors (I, II) were not acceptable owing to
high amplitude of T waves. Interrogation of the S-ICD
revealed appropriate sensing with no TWOS in either
standing or supine positions in all sensing vectors
(Figure 3A).
Following injection of 50 mg of pilsicainide (class IC
antiarrhythmic agent), a type 1 ECG was recorded in lead V1
in the second intercostal space (Figure 1D). A screening
ECG still showed adequate sensing in vector III (Figure 2C).
However, TWOS was observed in the primary vector of the
S-ICD electrogram (corresponding to vector III in the
screening ECG), which did not result in tachycardia detec-
tion or inappropriate shocks (Figure 3B). Isoproterenolpen access article under the CC BY-NC-ND license
http://dx.doi.org/10.1016/j.hrcr.2016.04.010
KEY TEACHING POINTS
 Brugada-pattern electrocardiogram shows dynamic
changes, and can be unmasked by a drug
challenge test.
 T-wave oversensing by the subcutaneous
implantable cardioverter-deﬁbrillator can occur
after drug challenge test with pilsicainide/
isoproterenol, or under conditions that cause
similar electrocardiogram changes in patients with
Brugada syndrome.
 The drug challenge test may be useful in evaluating
the appropriateness of subcutaneous implantable
cardioverter-deﬁbrillator placement in patients
with a life-threatening arrhythmia.
Heart Rhythm Case Reports, Vol 2, No 5, September 2016392infusion was followed by pilsicainide injection (Figure 1E),
but all sensing vectors were unacceptable owing to augmen-
tation of the T waves (Figure 2D). TWOS was still observed,
but only in the primary vector of S-ICD recorded in the
supine position (Figure 3C). No appropriate or inappropriate
shocks have occurred for up to 1 month after S-ICD
implantation.A C D
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Figure 1 A: In the baseline electrocardiograms (ECGs) of this 51-year-old mal
space. B: The pulse generator was placed subcutaneously in the middle axillary li
C: One day after subcutaneous implantable cardioverter-deﬁbrillator (S-ICD) impl
high costal ECG recordings. D:After 50 mg pilsicainide injection, type 1 ECG appe
followed by pilsicainide injection, and the amplitude of the J-point in the right prDiscussion
To date, the signiﬁcance of the drug challenge test as a
screening tool before S-ICD implantation in BrS remains
unknown. Although all sensing vectors were appropriate
during preimplant screening in this patient, only 1 vector was
acceptable on the day following S-ICD implantation; fur-
thermore, this became unacceptable after the drug challenge
test with pilsicainide and isoproterenol, and led to TWOS in
the S-ICD recording. Our report demonstrates that the drug
challenge test may be useful in evaluating the appropriate-
ness of S-ICD indication in those patients with BrS.
The Brugada-pattern ECG is prone to dynamic ECG
changes, and is unmasked by a provocation test with sodium-
channel blockers;5 this may lead to inadequate sensing of the
S-ICD system by changes in the QRS/T ratio. TWOS is one
of the main causes of inappropriate shocks in patients
implanted with an S-ICD.2 Preimplant screening utilizing
surface electrodes is effective only if a single lead con-
sistently falls within the designated area throughout a
10-second period in both supine and standing positions.
Screening tests conducted only at rest may be inadequate for
the prediction of the TWOS in S-ICD candidates with BrS.
This is because ST-segment augmentation in the right
precordial leads is observed in various daily life situations
such as during sleep, following a meal,6 after exercise,7 andE
e patient, type 1 ECG was observed only in lead V1 in the third intercostal
ne with the electrode inserted subcutaneously parallel to the sternal midline.
antation, only type 2 Brugada-pattern ECGs were observed including in the
ared in lead V1 in the second intercostal space. E: Isoproterenol infusion was
ecordial leads decreased.
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Figure 2 A: In the baseline screening electrocardiogram, all sensing vectors were appropriate in both supine and standing positions. B: One day after
subcutaneous implantable cardioverter-deﬁbrillator (S-ICD) implantation, only vector III was acceptable.C:After 50 mg pilsicainide injection, vectors I and II in
the supine position became inappropriate owing to augmentation of the T waves. Vector III remained appropriate. D: Finally, after isoproterenol infusion,
T-wave augmentation was observed in vector III in the supine position in addition to vectors I and II, and all sensing vectors were no longer acceptable.
393Kamakura et al Drug Challenge Test in a BrS Patient Implanted With an S-ICDin the febrile state.8 To date, the morphology of ECG
templates of sensing vectors derived from repeated ECG
recordings and drug challenge tests have not been evaluated.
This study provides important information in that the appro-
priate sensing vectors can change day-to-day, or owing to
drug provocation testing in patients with BrS. TWOS by the
S-ICD can occur after a drug challenge test with pilsicainide/
isoproterenol, or under conditions that cause similar ECG
changes in patients with BrS. A preimplant drug challenge test
may be applicable even in patients with a spontaneous type 1
ECG. Furthermore, a considerable number of patients with
early repolarization syndrome are reported to show a Brugada-
pattern ECG only in the high intercostal spaces.9 Drug
challenge tests may also be useful for prediction of TWOS
in those S-ICD candidates with lethal arrhythmic disorders
such as early repolarization syndrome.
The QRS/T ratio also changes during exertion, and
TWOS is often associated with exercise in patients ﬁtted
with an S-ICD.10 The importance of obtaining sensing
templates during exercise testing prior to implantation has
been demonstrated.10 In the present study, the amplitude ofT waves in the screening ECGs increased after isoproterenol
infusion (Figure 3D), and previously appropriate sensing
vectors were no longer acceptable. The isoproterenol infu-
sion test can be an alternative to exercise screening.
This patient has not experienced inappropriate shocks due
to TWOS after implantation. A new S-ICD sensing algo-
rithm that uses correlation of the existing complex to
previous complexes was reported to reduce the number of
inappropriate episodes due to TWOS by approximately
30%–40% without compromising detection of ventricular
arrhythmias.11 Further follow-up is needed to evaluate the
signiﬁcance of the drug challenge test in patients with BrS.Conclusions
Drug challenge testing with pilsicainide and isoproterenol
unmasked an unsuitable BrS patient formerly thought to be
eligible for S-ICD implantation at baseline. Our report
demonstrates that the drug challenge test may be useful in
evaluating the appropriateness of an indication for S-ICD in
patients with BrS.
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Figure 3 A: Subcutaneous implantable cardioverter-deﬁbrillator (S-ICD) recording showed normal sensing in the baseline 1 day after implantation. B: After
50 mg of pilsicainide injection, T-wave oversensing (TWOS) (red arrow) appeared in the primary vector, corresponding to vector III in the screening
electrocardiogram. C: TWOS was still observed after isoproterenol infusion in the primary vector in the supine position. TWOS observed after pilsicainide and
isoproterenol infusion did not result in tachycardia detection. Primary, secondary, and alternate vectors of the S-ICD electrogram correspond to vectors III, II, and
I of the screening electrocardiogram, respectively. S ¼ sensed ventricular event in the normal heart rate range.
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